Snapshot · The Peter Attia Drive
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
Where this was said
At 47:00 · chapter starts 46:30
Peter closes the main argument by separating his skepticism of the gray-market wellness ecosystem from any skepticism of peptide science itself. Insulin and GLP-1 agonists demonstrate what the class can achieve. The broader pipeline is substantial: roughly 100 approved peptide drugs, 150 in clinical trials, 600 to 700 in preclinical development. [1] — Peter Attia "Roughly 100 peptide drugs are already approved; 150 more are in trials. The real near-term promise is in metabolism, infectious disease, di…" 46:50 The areas of genuine near-term promise are metabolism, infectious disease, diagnostics, and cancer — where the specificity of peptides can be a decisive advantage. The irony he highlights is sharp: the applications most aggressively sold in the wellness world — brain boosting, tissue repair, recovery, and longevity — are exactly where peptides face the steepest scientific barriers. The blood-brain barrier makes central nervous system effects extremely difficult. Tissue repair is biologically complex. Broad claims about healing, regeneration, and optimization are harder to validate than claims about a defined disease state. For a healthy person seeking modest performance gains, the risk-benefit math changes quickly when product quality is uncertain and evidence is speculative.
Roughly 100 peptide drugs are already approved; 150 more are in trials. The real near-term promise is in metabolism, infectious disease, diagnostics, and cancer. The irony: the uses most aggressively marketed in the wellness world — brain boosting, recovery, tissue repair — are exactly where peptides face the most difficult scientific barriers.
A large Harvard study found that a wandering mind is an unhappy mind — people report greater happiness when their attention is tethered to the present, even if the task is unpleasant.
A key study finding that we have a 'credit card's worth of plastic' in our bodies was likely skewed because researchers used nitrile gloves that shed plastic particles onto the microplastic detector.
Emotionally sensitive people have a hyperactive amygdala, an underactive prefrontal cortex, and a frayed connection between the two — making emotional regulation structurally harder.
Rejection sensitivity can be observed as early as age 2 or 3, suggesting it has strong developmental and likely genetic roots.
A Yale study found that non-judgmental observation of emotions — without rushing to resolve them — reduces activation in the brain, making it a powerful regulation tool.
Dan Gilbert's research found that the psychological immune system — the brain's ability to justify and find satisfaction in choices — activates most powerfully when a decision is perceived as irreversible.
Barry Schwartz's research found that maximizers — people who try to optimize every decision — tend to achieve objectively better outcomes but report lower happiness than satisficers who choose 'good enough.'
Research consistently shows that while people may initially regret poor decisions, in the long run they regret the decisions they didn't make — inaction — far more than the ones they took.
A study showed that men in committed relationships who briefly viewed 10 attractive women's faces reported a measurable decrease in relationship satisfaction immediately afterward, illustrating evolutionary mismatch with modern media.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.